1. Home
  2. EVF vs GANX Comparison

EVF vs GANX Comparison

Compare EVF & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eaton Vance Senior Income Trust

EVF

Eaton Vance Senior Income Trust

HOLD

Current Price

$4.99

Market Cap

90.3M

Sector

Finance

ML Signal

HOLD

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$1.88

Market Cap

76.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVF
GANX
Founded
N/A
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
90.3M
76.4M
IPO Year
1998
2021

Fundamental Metrics

Financial Performance
Metric
EVF
GANX
Price
$4.99
$1.88
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$7.50
AVG Volume (30 Days)
49.9K
655.7K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
31.46
EPS
N/A
N/A
Revenue
N/A
$55,180.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.85
$1.41
52 Week High
$5.75
$4.34

Technical Indicators

Market Signals
Indicator
EVF
GANX
Relative Strength Index (RSI) 50.88 56.36
Support Level $4.92 $1.73
Resistance Level $5.02 $2.12
Average True Range (ATR) 0.04 0.11
MACD 0.00 0.02
Stochastic Oscillator 50.00 70.21

Price Performance

Historical Comparison
EVF
GANX

About EVF Eaton Vance Senior Income Trust

Eaton Vance Senior Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide a high level of current income consistent with the preservation of capital, by investing in senior, secured floating-rate loans. The trust invests in below-investment-grade floating-rate loans, which are considered speculative because of the credit risk of their issuers. Its portfolio of investment consists of aerospace and defense, automotive, beverage, building and development, business equipment and services, cable and satellite television, and other areas.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.

Share on Social Networks: